Previous studies have shown that high expression of FAK is positively correlated with shorter overall survival and progression‐free survival in patients with metastatic tumors.[2] Our study found that focal adhesion pathway molecules, especially FAK, are most significantly associated with the poor outcome of TNBC patients. The gene discussed is PTK2; the disease is metastatic neoplasm.